Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $491,734 | $398,204 | $214,203 | $140,833 |
| % Growth | 23.5% | 85.9% | 52.1% | – |
| Cost of Goods Sold | $68,845 | $51,967 | $34,393 | $21,884 |
| Gross Profit | $422,889 | $346,237 | $179,810 | $118,949 |
| % Margin | 86% | 86.9% | 83.9% | 84.5% |
| R&D Expenses | $12,648 | $93,150 | $19,789 | $16,936 |
| G&A Expenses | $167,740 | $47,021 | $53,785 | $23,477 |
| SG&A Expenses | $177,740 | $133,710 | $57,085 | $49,628 |
| Sales & Mktg Exp. | $10,000 | $86,689 | $3,300 | $26,151 |
| Other Operating Expenses | $37,377 | $32,565 | $1,098 | $0 |
| Operating Expenses | $227,765 | $259,425 | $77,972 | $66,564 |
| Operating Income | $195,124 | $86,812 | $101,838 | $52,385 |
| % Margin | 39.7% | 21.8% | 47.5% | 37.2% |
| Other Income/Exp. Net | $21,139 | $7,699 | $2,881 | $282 |
| Pre-Tax Income | $216,263 | $94,511 | $104,719 | $52,667 |
| Tax Expense | $52,374 | $23,101 | $21,640 | $13,185 |
| Net Income | $163,889 | $71,410 | $83,079 | $39,482 |
| % Margin | 33.3% | 17.9% | 38.8% | 28% |
| EPS | 1.38 | 0.67 | 0.8 | 0.38 |
| % Growth | 106% | -16.3% | 110.5% | – |
| EPS Diluted | 1.31 | 0.63 | 0.75 | 0.37 |
| Weighted Avg Shares Out | 118,458 | 106,280 | 103,375 | 103,379 |
| Weighted Avg Shares Out Dil | 124,944 | 113,753 | 111,376 | 107,796 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16,064 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $37,774 | $32,881 | $1,239 | $192 |
| EBITDA | $232,898 | $119,693 | $103,077 | $52,577 |
| % Margin | 47.4% | 30.1% | 48.1% | 37.3% |